Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 9, 2026
Reporting Period: Single event date (January 9, 2026)
Business Context: The filing serves as a Regulation FD disclosure to distribute a corporate slide presentation and a press release to the investment community. These materials provide updates on business progress and outline the company's outlook for 2026.
Key Financial Metrics
The provided filing text does not contain specific financial data. It references attached exhibits (99.1 and 99.2) for details on progress and outlook but does not explicitly state values for:
- Revenue
- Profit or Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Note: As this is a Form 8-K referencing external exhibits, specific financial metrics are not present in the main body of this text.
Material Changes
The filing does not report specific material changes in financial condition or operations within the text itself. The primary material event is the issuance of:
- A corporate slide presentation dated January 2026.
- A press release issued on January 9, 2026, highlighting recent progress and the 2026 outlook.
Guidance, Outlook, and Risks
Outlook: The company issued a press release outlining its 2026 outlook, though specific targets or guidance figures are not detailed in the filing text.
Management Commentary: The company presents updates to the investment community via slide presentations and press releases.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in Item 7.01 and the attached exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. The company explicitly undertakes no obligation to update, supplement, or amend the attached materials except as required by law.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Slide Presentation) for specific operational milestones and pipeline updates.
- Review Exhibit 99.2 (Press Release) for detailed 2026 outlook and recent progress highlights.
- Verify the company's current cash position and burn rate in the most recent 10-Q or 10-K, as this 8-K does not provide liquidity data.
- Confirm the status of any clinical trials or regulatory filings mentioned in the attached exhibits.